Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19

Guérin et al., Asian J. Medicine and Health, July 15, 2020, doi:10.9734/ajmah/2020/v18i730224 (date from preprint)

May 2020

Source PDF All Studies Meta AnalysisMeta

Mean clinical recovery time reduced from 26 days (SOC) to 9 days, p<0.0001 (HCQ+AZ) or 13 days, p<0.0001 (AZ). No cardiac toxicity. Small retrospective study of 88 patients with case control analysis with matched patients.

Important missing comments or errors? Let us know.

risk of death, 61.4% lower, RR 0.39, p = 1.00, treatment 0 of 20 (0.0%), control 1 of 34 (2.9%), NNT 34, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).

recovery time, 65.0% lower, relative time 0.35, p < 0.001, treatment 20, control 34.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Guérin et al., 31 May 2020, retrospective, France, peer-reviewed, 8 authors, dosage 600mg days 1-10, 7-10 days, this trial uses multiple treatments in the treatment arm (combined with AZ) - results of individual treatments may vary.

All Studies Meta Analysis Submit Updates or Corrections

This Paper HCQ All

Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19

Violaine Guérin, Pierre Lévy, Jean-Louis Thomas, Thierry Lardenois, Philippe Lacrosse, Emmanuel Sarrazin, Natacha Regensberg-De Andreis, Martine Wonner

Asian Journal of Medicine and Health, doi:10.9734/ajmah/2020/v18i730224

Aims: The challenge regarding COVID-19 is to prevent complications and fatal evolution. Azithromycin (AZM) and hydroxychloroquine (HCQ) have proven their antiviral effect in vitro. We aimed to assess the efficacy and safety of AZM alone or combined to HCQ, prescribed, at an early stage, in patients with Covid-19, in a primary care setting. Study Design: Retrospective observational study. Place and Duration of Study: Patients have been followed by private practitioners in France, between March and April 2020. Methodology: Eighty-eight patients received either no or a symptomatic treatment (NST) (n=34) or AZM alone (n=34) or AZM+HCQ (n=20). The efficacy end point was the time to clinical recovery

Authors' contributions This work was carried out in collaboration among all authors. Authors VG and JLT designed the study and wrote the first draft of the manuscript. Authors VG, TL, ES, NRA, P. Lacrosse and MW followed the patients. Author P. Lévy performed the statistical analysis. All authors read and approved the final manuscript. ETHICAL APPROVAL It is not applicable. COMPETING INTERESTS Authors have declared that no competing interests exist.

References

Agrawal, Goel, Gupta, Emerging prophylaxis strategies against COVID-19, Monaldi Archives for Chest Disease, doi:10.4081/monaldi.2020.1289

Arshad, Kilgore, Chaudhry, Jacobsen, Wang et al., Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19, Int J Infect Dis, doi:10.1016/j.ijid.2020.06.099

Barbosa, Da Silva, Costa, Castro, Razuk-Filho et al., Empirical treatment with hydroxychloroquine and azithromycin for suspected cases of COVID-19 followed by telemedicine

Chen, Hu, Zhang, Jiang, Han et al., Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial, Med Rxiv, doi:10.1101/2020.03.22.20040758

Fox, Mechanism of action of hydroxychloroquine as an antirheumatic drug, Semin Arthritis Rheum, doi:10.1016/s0049-0172(10)80012-5

Gao, Tian, Yang, Break through: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends, doi:10.5582/bst.2020.01047

Garcia-Cremades, Solans, Hughes, Ernest, Wallender et al., Optimizing hydroxychloroquine dosing for patients with COVID19: An integrative modeling approach for effective drug repurposing, Clin Pharmacol Ther, doi:10.1002/cpt.1856

Gautret, Lagier, Parola, Hoang, Meddeb et al., Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study, Travel Med Infect Dis, doi:10.1016/j.tmaid.2020.101663

Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105949

Guan, Ni, Hu, Liang, Ou et al., for the China medical treatment expert group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China, New Engl J Med, doi:10.1056/NEJMoa2002032

Keyaerts, Vijgen, Maes, Neyts, Van Ranst, In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine, Biochem Biophys Res Commun, doi:10.1016/j.bbrc.2004.08.085

Kim, Jang, Parl, Kim, Hwang et al., Treatment response to hydroxychloroquine, lopinavirritonavir, and antibiotics for moderate COVID-19: A first report on the pharmacological outcomes from South Korea, Med Rxiv, doi:10.1101/2020.05.13.20094193

Lagier, Million, Gautret, Colson, Giraud-Gatineau, Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/ azithromycin and other regimens in Marseille, France: A retrospective analysis, Travel Med Infect Dis, doi:10.1016/j.tmaid.2020.101791

Liu, Cao, Xu, Wang, Zhang et al., Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov, doi:10.1038/s41421-020-0156-0

Mackenzie, Dose refinement in longterm therapy of rheumatoid arthritis with antimalarials, Am J Med, doi:10.1016/0002-9343(83)91269

Menzel, Akbarshahi, Bjermer, Uller, Azithomycin induces anti-viral effects in cultured bronchial epithelial cells from COPD patients, Sci Rep, doi:10.1038/srep28698

Meo, Klonoff, Akram, Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19, Eur Rev Med Pharmacol Sci, doi:10.26355/eurrev_202004_21038

Million, Lagier, Gautret, Colson, Fournier et al., Early treatment of 1061 COVID-19 patients with hydroxychloroquine and azithromycin, Marseille, France, Travel Med Infect Dis, doi:.org/10.1016/j.tmaid.2020.101738

Saleh, Gabriels, Chang, Kim, Mansoor et al., The effect of chloroquine, hydroxychloroquine and azithromycin on the corrected QT interval in patients with SARS-CoV-2 infection, Circ Arrhythm Electrophysiol, doi:10.1161/CIRCEP.120.008662

Savarino, Trani, Donatelli, Cauda, Cassone, New insights into the antiviral effects of chloroquine, Lancet Infect Dis, doi:10.1016/S1473-3099(06)70361-9

Vincent, Bergeron, Benjannet, Erickson, Rollin et al., Chloroquine is a potent inhibitor of SARS coronavirus infection and spread, Virol J, doi:10.1186/1743-422X-2-69

Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, doi:10.1038/s41422-020-0282-0

Yan, Zou, Sun, Li, Xu et al., Anti-malaria drug chloroquine is highly effective in treating avian Influenza A HRN1 virus infection in a animal model, Cell Res, doi:10.1038/cr.2012.165

Yao, Ye, Zhang, Cui, Huang et al., In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2), Clin Infect Dis, doi:10.1093/cid/ciaa237

Download Image

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

@CovidAnalysis

FAQ

Public domain CC0 1.0